Main Article Content
Aims: Determining epidemiological characteristics and treatment outcome of endometrial carcinoma (EC) patients treated at Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt from Jan 2000 to Dec 2013 inclusive.
Study Design: Retrospective study.
Place and Duration of Study: Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Methodology: Clinical data of 226 EC patients were retrospectively abstracted from the records. Data collected included presenting symptoms, detailed examination and investigations, the treatment protocol, and the outcome.
Results: Post-menopausal females were 183 (81%). The incidence of disease was 75.7% among cases with BMI 30-39.9. Forty-two (18.6%) were diagnosed with positive family history. Postmenopausal bleeding was the most common presenting symptom (79.6%). Endometrioid adenocarcinoma was the most common pathology (85.4%) and 48 (21.2%) were diagnosed as grade III.Eighty-four (37.2%) were stage IB and 62 (27.4%) were stage 1A.EC was classified into Low-risk cases (FIGO 2009 stage IA, grade 1 or 2, of endometrioid type histology, intermediate-risk cases ( stage IA grade 3 endometrioid EC&IB grade 1,2 ) and high-risk cases( FIGO stage IB of grade 3 or non-endometrioid histology, stage II, and any stage with non-endometrioid histology). Most of our patients were intermediate risk [95 patients (42.1%)] followed by high risk [81 patients (35.8%)]. Adjuvant treatment was received by 183 patients (90% of whom were intermediate and high risk). Combined EBRT plus brachytherapy was not given to low-risk patients. The 5- year DFS & OS were 46.4% & 65.1% respectively.BMI, ECOG, tumour grade, staging, using EBRT plus VBT and using combined chemotherapy and radiotherapy were the significant prognostic factors.
Conclusion: The majority of our EC cases were obese post-menopausal women having early stages and intermediate-risk disease. Serious investigation of postmenopausal bleeding is a must and tailoring the therapy of EC based on the risk category is worthy.
Van Nyen T, Moiola CP, Colas E, Annibali D, Amant F. Modeling endometrial cancer: Past, present, and future. Int J Mol Sci. 2018;19(8):2348-2352.
Alshahrani S, Soliman AS, Hablas A, Ramadan M, Meza J, Remmenga S, et al. Changes in uterine cancer incidence rates in Egypt. Obstetrics and Gynecology International. 2018;2018:1-10.
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35): 4225-4230.
Pant A, Bristow R. Cancer of the uterine corpus. In: Joseph, H. K., Guile, M. & Bienstock, J. (Eds.) John Hopkins manual of genecology and obstetrics. 4th Ed. Philadelphia: Lippincott Williams & Wilkins. 2011;50.
Balasubramaniam G, Sushama S, Rasika B, Mahantshetty U. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pac J Cancer Prev. 2013; 14(2):977-980.
Jayaraman M, Radhakrishnan R, Mathews CA, Yan M, Husain S, Moxley K, et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. Genes & Cancer. 2017;8(5-6):566-576.
Conlon N, Leitao MM, Abu-Rustum NR, Soslow R. Grading uterine endometrioid carcinoma. Am J Surg Pathol. 2014; 38(12):1583-1587.
Kong A, Johnson N, Kitchener HC, Lawrie T. Adjuvant radiotherapy for stage I endometrial cancer: An updated cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(21):1625- 1634.
Nout RA, Smit VT, Putter H, Jürgenliemk-SchulzI M, JobsenJ J, Lutgens LCHW, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high‐ intermediate risk (PORTEC‐2): An open‐label, non‐inferiority, randomised trial. Lancet. 2010;375(9717):816–823.
Randall M, Filiaci V, McMeekin D, Yashar CM, Mannel R, Salani R, et al. A phase 3 trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high‐risk, early‐stage endometrial cancer: A gynecology oncology group study. Int J Rad Oncol Biol Phys. 2017;99(5):1313.
Patni R. Current concepts in endometrial cancer. USA: Springer. 2017;30.
Martin-Hirsch PPL, Bryant A, Keep SL, Kitchener H, Lilford R. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev. 2011;6: CD001040.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A gynecologic oncology group STUDY. Gynecol Oncol. 2004;92(3):744-751.
Setakornnukul J, Petsuksiri J, Wanglikitkoon S, Warnnissorn M, Thephamongkhol K, Chasilp Y, et al. Long term outcomes of patients with endometrial carcinoma treated with radiation - Siriraj Hospital experience. Asian Pac J Cancer Prev. 2014;15(5):2279-2285.
Signorelli M, Lissoni AA, De Ponti E, Grassi T, Panti S, Fruscio R. Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer. J Gynecol Oncol. 2015;26(4):284-292.
Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, et al. Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2010;6(6):937-944.
Van den Bosch A, Mertens H. Implementation of laparoscopic surgery for endometrial cancer: Work in progress. Facts Views Vis Obgyn. 2016; 8(1):23.
Wan Nor Asyikeen WA, Siti-Azrin AH, Che Jalil NA, Zin AAM, Othman NH. Median survival time of endometrial cancer patients with lymphovascular invasion at the Hospital Universiti Sains Malaysia. Malays J Med Sci. 2016;23(6):44-51.
Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019;145(7):1719-1730.
Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: A meta-analysis. Public Health. 2015;129(7): 872-880.
Suskic A, Suskic SH, Opric D, Maksimovic S. Obesity as a significant risk factor for endometrial cancer. IJRCOG. 2016;5:(9): 2950-2951.
Jimñnez-López JS, Tejerizo-Garcia A, Álvarez-Conejo C, Guillen–Gamez C, Seoane-Ruiz JM, Perez-Sagaseta C, et al. Tumor recurrence and tumor-related mortality in endometrial cancer: Analysis in 276 patients. Indian J Cancer. 2015;52(4): 682-684.
Nicholas Z, Hu N, Ying J, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. Am J Clin Oncol. 2014;37(2):131-134.
Saed L, Varse F, Baradaran HR, Moradi Y, Khateri S, Frigerg E, et al. The effect of diabetes on the risk of endometrial cancer: An updated a systematic review and meta-analysis. BMC Cancer. 2019;19(1):527.
Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2010;172(12):1394-1403.
Zaino R, Carinelli S, Ellenson L. Tumours of the uterine corpus: Epithelial tumours and precursors. WHO Classification of Tumours of the Female Reproductive Organs. 4th ed. Lyon, France: IARC Press. 2014;125.
Guinney J, Dienstmann R, Wang X, de Reynies, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11): 1350-1356.
Adekanbi AOA, Jimoh MA, Ajani Mustapha Akanji, Fawole Adeniran Olubukola. Endometrial cancer in Ibadan: Epidemiological and clinico-pathological Features-10 year review. New York Sci J. 2016;9(3):19-23.
Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer. Obstet Gynecol. 2015;125(1):89-98.
Pinar G, Ayhan A. Survival determinants in endometrial cancer patients: 5-years experience. Archives of Nursing Practice and Care. 2017;3(1):012-015.
Gao Y, Dai X, Chen L, Lee A, Tong M, Wise M, et al. Body mass index is positively associated with endometrial cancer in chinese women, especially prior to menopause. J Cancer. 2016;7(9):1169-1173.
Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, et al. Baseline risk of recurrence in stage I–II endometrial carcinoma. J Gynecol Oncol. 2017;29(1):e9.
Yen M-S, Chen T-H, Ke Y-M, Hsu K, Chen J, Yu M, et al. Clinicopathologic features and treatment outcomes in patients with Stage I, high-risk histology or high-grade endometrial cancer after primary staging surgery: A Taiwanese gynecologic oncology group study. J Clin Med. 2018; 7(9):254.
Craighead PS, Sait K, Stuart GC, Arthur K, Nation J, Duggan M, et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol. 2000;77(2):248-253.
Karateke A, Selcuk S, Asoglu MR, Namazov A, Tug N, Cam C, et al. Prognostic factors affecting survival in endometrial carcinoma. J Turk Soc Obstet Gynecol. 2012;9(1):42-46.
Jhingran A, Burke T, Eife P. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003;56(2):1366-1372.
Bajracharya S, Juan F. Prognostic factors in endometrial cancer. Journal of Institute of Medicine. 2013;35(1):9-17.
Zanders MJ, Boll D, van Steenbergen L, Poll-France L, Haak H. Effect of diabetes on endometrial cancer recurrence and survival. Maturitas. 2013;74(1):37-43.
Arem H, Irwin ML. Obesity and endometrial cancer survival: A systematic review. Int J Obes (Lond). 2012;37(5):634-639.
Modesitt SC, Tian C, Kryscio R, Higpen JT, Randalld ME, Gallione HH, et al. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: A gynecologic oncology group study. Gynecol Oncol. 2007;105:(1):59-65.
Mauland KK, Trovik J, Wik E, Raeder MB, Nyolstad TS, Stefansson IM, et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer. 2011;104(6):921-926.
Wright JD, Cham S, Chen L, Burke WM, Hou JY, Tergas AI, et al. Utilization of sentinel lymph node biopsy for uterine cancer. Am J Obs Gyn. 2017;216(6): 594.e1-594.e13.
Blake P, Swart AM, Orton J. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and meta-analysis. Lancet. 2009; 373(2):137-146.
Han AR, Kwon YS, Kim D, Kim JH, Kim YM, Kim YT, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009;19(1):147-151.
Yoo S, Hegarty SE, Mishra MV, Patel N, Cantrell LA, Timothy N, Showalter TN. Definitive radiation therapy for stage I-II endometrial cancer. Am J Clin Oncol. 2017;40(6):582-589.
Sorbe B, Nordström B, Mäenpää J, Kuhelj J, Kuhelj D, Okkan S, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer. Int J Gynecol Cancer. 2009;19(5):873-878.
Therasakvichya S, Kuljarusnont S, Petsuksiri J, Chaopotong P, Achariyapota V, Srichaikul P, et al. Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences. J Gynecol Oncol. 2016; 27(5):e48.
Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4): e631-638.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. 2016;17(8):1114-1126.
Galaal KA, Moundhri MA, Bryant A, Lopes AD, Theresa A, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database of Systematic Reviews. 2014;15(5):32-45.